A study published in Osteoporosis International focused on the changes that have occurred over the course of the pandemic for patients with osteoporosis and found that there have been delays in dual-energy X-ray absorptiometry (DXA) scanning, problems with medication supply, a decrease in face-to-face consultations, and reductions in parenteral medication delivery.
“Based on 16,235 pairs of zoledronic acid and denosumab initiators (for osteoporosis), we found a greater risk (HR 1.25, 95% CI 1.04-1.50) of atrial fibrillation with zoledronic acid vs denosumab: an absolute risk difference of 3.69 events per 1000 person-years,” said Seoyoung Kim, MD, ScD.
Dr Joan Lo, MD, a research scientist with the Kaiser Permanente Northern California Division of Research, said: “We found that hip fracture risk in women did not differ if women stopped bisphosphonate use after five years or stayed on the medication for 10 years. Whether there is a benefit to staying on the drug for seven years needs to be further studied in randomized trials.”
The results of a study presented at ACR 2020 demonstrate that a greater proportion of patients were initiated on denosumab compared with bisphosphonates for the first time—18.5% compared with 16.9%— in 2018.
“The main take home message is to pay attention to the prevention and treatment of GIOP while prescribing steroids to the patients because the side effects is steroids are not benign," Shikha Singla, MD, said.
Non-heterosexual minority men have a greater risk of poor bone health than heterosexual men, and this risk appears to be independent of lifestyle and psychosocial factors, suggests a study published in the American Journal of Human Biology.